您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > AMG 337
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AMG 337
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AMG 337图片
CAS NO:1173699-31-4
包装与价格:
包装价格(元)
5mg电议
25mg电议

产品介绍
AMG 337 是一种有效的、具有口服活性的选择性 MET 激酶抑制剂,对 WT MET、H1094R MET、M1250T MET、HGF 刺激的 pMET(PC3 细胞)的 IC50 值为 1、1、4.7、5、21.5、1077 和 \u003e4000 nM MET、V1092I MET、Y1230H MET 和 D1228H MET。 AMG 337 抑制 MET 扩增的癌细胞系中 MET 和下游效应子的磷酸化,从而抑制 MET 依赖性细胞增殖和诱导细胞凋亡。
Cas No.1173699-31-4
化学名(R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one
Canonical SMILESCN1N=CC(C2=CN3C([C@@H](C)N4C=CC(N=CC(OCCOC)=C5)=C5C4=O)=NN=C3C(F)=C2)=C1
分子式C23H22FN7O3
分子量463.46
溶解度≥ 46.3mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50:< 5 nM in enzymatic assays

AMG 337 is a MET inhibitor.

MET receptor with its ligand can promote cell survival, proliferation, and invasion. The activation of MET signaling is a common regulator of various human cancer types, and thus, inhibition of MET signaling is an promising therapeutic opportunity for the treatment of cancer.

In vitro: AMG 337 could effectively inhibit MET kinase activity, and AMG 337 also showed great selectivity for MET when tested against a panel of over 400 protein as well as lipid kinases. In addition, AMG 337 was found to inhibit HGF-dependent MET phosphorylation. Furthermore, AMG 337 could only affect the viability of two gastric cancer cell lines with amplification of the MET gene. The IC50 values of AMG 337 for the two sensitive cell lines was less than 50 nM, whereas over 10 μM in all other tested cell lines [1].

In vivo: In anima study, it was found that the oral administration of AMG 337 led to the dose-dependent anti-tumor efficacy in MET amplified gastric cancer xenograft models, which was quite consistent with the PD modulation of MET signaling [1].

Clinical trial: A phase 1 clinical study is currently investigating the safety, tolerability and PK of AMG 337 in patients with solid tumors [2].

References:
[1] Paul E.  Hughes, et al. AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models. Cancer Res October 1, 2014 74; 728
[2] https://clinicaltrials. gov/ct2/show/NCT01253707 term=AMG+337&rank=1